AMENDMENTS TO THE CLAIMS

1. **(Currently Amended)** An implant for treating a medical condition of an eye, the implant comprising:

(a) a carrier, and;

(b) a botulinum neurotoxin complex having a molecular weight of about 900 kD, 700, kD, 500 kD or 300 kD, associated with the carrier, thereby forming an implant, wherein a therapeutic amount of the botulinum neurotoxin can be released from the carrier upon implantation of the implant into a patient to thereby treat a medical condition of an eye.

2.-3 **(Cancelled)**

4. **(Previously Presented)** The implant of claim 1, wherein the carrier is substantially biodegradable.

5. **(Previously Presented)** The implant of claim 1 wherein the botulinum neurotoxin is selected from the group consisting of botulinum neurotoxin serotypes A, B, C, D, E, F and G..

6. -7. **(Cancelled)**

8. **(Currently Amended)** A method for treating a condition of the eye, the method comprising the step of implanting into a patient a biodegradable implant comprising a botulinum neurotoxin complex having a molecular weight of about 900 kD, 700, kD, 500 kD or 300 kD associated with a carrier.

9.-13 **(Cancelled)**

14. **(New)** An implant for treating a medical condition of an eye, the implant comprising:

(a) a carrier, and;

(b) a botulinum type A neurotoxin complex, having a molecular weight of about 900 kD, associated with the carrier, thereby forming an implant, wherein a therapeutic amount of the botulinum neurotoxin can be released from the carrier upon implantation of the implant into a patient to thereby treat a medical condition of an eye